Atorvastatin added to a beta blocker in advanced cirrhosis of the liver
Tests atorvastatin plus a beta blocker in adults with decompensated cirrhosis.
Key facts
- Who runs it
- CAMC Health System
- Where
- Charleston, United StatesSee the site
- Trial code
- Registry title
- Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 50 people, planned
- Started
- 9 Sept 2025
- Expected to end
- Mar 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Atorvastatin 20 mg
- Placebo
- Record updated
- 25 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with decompensated cirrhosis (advanced liver scarring with serious problems) who already take a non-selective beta-blocker. It compares atorvastatin with placebo, both added to the beta-blocker.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Decompensated liver disease: fluid buildup in the belly (ascites), confusion from liver disease (hepatic encephalopathy), or bleeding from swollen veins (variceal bleed). Patients must come to CAMC Memorial Hospital or the CAMC-Gastroenterology Liver Clinic.
- Earlier treatment
- Must currently take a non-selective beta-blocker. Cannot be taking a statin now. Must agree to liver care at the CAMC-Gastroenterology Liver Clinic for 12 months.
Main reasons for not taking part
- Liver cancer (hepatocellular carcinoma)
- Ongoing alcohol use, more than one drink per week
- IV drug use or a history of not taking medicines as told
- Past statin intolerance, or taking medicines that interact with statins
- On the waitlist for a liver transplant
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Patients age of 18 years or older diagnosed with any form of decompensated liver disease defined as ascites, hepatic encephalopathy, or variceal bleed presenting at Charleston Area Medical Center (CAMC) Memorial Hospital or CAMC-Gastroenterology Liver Clinic
- Currently on an non-selective beta-blockers agreeing to have their liver disease managed by CAMC-Gastroenterology Liver Clinic as an outpatient for the 12-month follow-up period
Who cannot take part
- Patients currently on statin therapy
- Patients on the waitlist for liver transplantation
- Patients taking medications with known drug interactions with statins
- Patients exhibiting high-risk behaviors that could put them at risk for complications including IV substance use and history of medication non-adherence
- Patients with a history of statin intolerance
- Any patient <18 years of age
- Patients with hepatocellular carcinoma
- Patients with ongoing alcohol use (self-reported consumption of more than one alcoholic drink per week)
- Patients not able to give informed consent or patients belonging to vulnerable categories as the Federal Regulations or Common Rule
Where in United States
- Charleston Area Medical CenterCharleston, United StatesContact: Nadeem Anwar, MDTaking people
About the trial
What the trial wants to find out
Decompensated cirrhosis (liver disease) occurs when liver function decreases to the extent that serious complications develop and can include internal bleeding, fluid buildup in the abdomen, or mental confusion. This reduced decreased liver function subsequently decreases life expectancy. There is a critical need for strategies to delay progression to decompensation and reduce the occurrence of serious complications. Currently, limited therapeutic options are available for managing decompensated liver disease, with beta-blockers (BB) being the only proven medication with significant benefits in preventing disease progression. Statins have been historically under- prescribed in cirrhosis due to concerns of liver damage. However, there is emerging evidence that statin use may be beneficial and able to lessen liver disease worsening, with studies demonstrating its safety. Thus, we aim to conduct a pilot randomized controlled trial (RCT) study of 50 subjects comparing the outcomes of decompensated cirrhotic patients receiving the statin, atorvastatin, and a non-selective beta-blocker (NSBB) versus those receiving NSBB plus placebo. Both groups will be followed for 12 months to investigate the feasibility, safety, and efficacy of combination therapy.
The 2 groups in the trial
- NSBB plus statinExisting treatment, for comparison
Atorvastatin 20 mg once daily along with previously prescribed NSBB
Treatment: Atorvastatin 20 mg
- NSBB plus placeboPlacebo, for comparison
Placebo once daily along with previously prescribed NSBB
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Pilot Study of Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis
- Plain-language title
- Atorvastatin added to a beta blocker in advanced cirrhosis of the liverGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 25 February 2026